AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsMelphalanTransplantation, HomologousTransplantation ConditioningCombined Modality TherapyTreatment OutcomeRemission InductionStem CellsSalvage TherapyDisease-Free SurvivalEtoposideHodgkin DiseaseCyclophosphamideLymphoma, Non-HodgkinMyeloablative AgonistsCytarabineRecurrenceCarmustineSurvival RateHematopoietic Stem Cell MobilizationBone Marrow TransplantationGraft vs Host DiseaseThiotepaBone Marrow PurgingVincristineSurvival AnalysisHematologic NeoplasmsLymphoma, Mantle-CellWhole-Body IrradiationAmyloidosisRetrospective StudiesDoxorubicinHematopoietic Stem CellsBusulfanBoronic AcidsDexamethasonePrognosisPyrazinesGraft SurvivalAntibodies, Monoclonal, Murine-DerivedFollow-Up StudiesAntineoplastic Agents, AlkylatingLymphoma, FollicularAntigens, CD34AutograftsLymphoma, T-Cell, PeripheralLiver TransplantationThalidomideIfosfamideAntineoplastic AgentsInduction ChemotherapyTime FactorsMesenchymal Stem Cell TransplantationGranulocyte Colony-Stimulating FactorLeukapheresisPrednisoneLymphomaPodophyllotoxinLymphoma, Large B-Cell, DiffuseNeoplasm, ResidualTransplantation ChimeraMaintenance ChemotherapyTissue DonorsCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteCell TransplantationKidney TransplantationLymphoma, B-CellEnteropathy-Associated T-Cell LymphomaEmbryonic Stem CellsMyelodysplastic SyndromesMitoxantroneIdarubicinLeukemia, Plasma CellNeoplasms, Second PrimaryInfusions, SpinalCisplatinCarboplatinProspective StudiesAdult Stem CellsBlood Component RemovalImmunosuppressive AgentsChemotherapy, AdjuvantHistocompatibility TestingNeoplasm Recurrence, LocalDrug Administration ScheduleAntibodies, MonoclonalFeasibility StudiesLeukemia, MyeloidFatal OutcomeCell DifferentiationKeratins, Type IINeutropeniaLife TablesHistocompatibility
ASCTLymphomaMarrow transplantationAllogeneicRefractoryMultiple myelomaRituximabRetrospective analysisTherapiesBEAMBone marrowTransplantImmunotherapyProgenitorTherapyCombined chemotherapy and radiationLymphomasSurvivalTumorsHSCTTumor cellsPost-transplantationIrradiationClinicalMyelomaHematopoietic stemPatientMalignanciesMalignant cellsInfusionAntigenMETHODSTreatmentAcute MyelogenSequentialPhasePediatric
ASCT11
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. (cun.es)
  • Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas. (cun.es)
  • High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. (biomedcentral.com)
  • A randomized controlled trial, incorporating a GA and comparing age-adapted HCT-ASCT treatment with conventional chemotherapy is needed. (biomedcentral.com)
  • The primary objective is to demonstrate that intensified chemotherapy followed by consolidating HCT-ASCT is superior to conventional chemotherapy with rituximab, MTX, procarbazine (R-MP) followed by maintenance with procarbazine in terms of progression free survival (PFS). (biomedcentral.com)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). (lu.se)
  • Additional data presented in an oral presentation at ASCO (Abstract #8013) demonstrate that adding BEXXAR to BEAM (BCNU, etoposide, ara-C, and melphalan) chemotherapy as a conditioning regimen prior to autologous stem cell transplant (ASCT) in patients with relapsed or high-risk chemosensitive diffuse large B-cell lymphoma (DLBCL) resulted in 78% of the patients achieving a complete remission following the transplant. (salesandmarketingnetwork.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • In this ongoing Phase II multicenter study, 55 heavily pretreated patients with relapsed/refractory DLBCL, including almost 50% without a response to autologous stem cell transplantation (ASCT), were treated with fludarabine/cyclophosphamide lymphodepletion, followed by a dose of JCAR17. (medpagetoday.com)
  • Here we present an analysis of SPM incidence and profile the SPM type to determine the impact of autologous stem cell transplantation (ASCT) and lenalidomide exposure in 4358 patients treated on study. (nyu.edu)
Lymphoma41
  • However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined. (cun.es)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • Depending on the patient's performance status, his/her ability to tolerate chemotherapy, the type of lymphoma, the stage of disease and different prognostic factors, one or more courses of the full sequence can be omitted or dose reduced. (wikipedia.org)
  • Waldenström's macroglobulinemia is a slow-growing form of non-Hodgkin lymphoma that originates in white blood cells known as B lymphocytes. (sciencedaily.com)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • That doesn't even count all the patients with leukemia or lymphoma cured primarily by chemotherapy. (sciencebasedmedicine.org)
  • We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy. (karger.com)
  • Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (karger.com)
  • Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma. (karger.com)
  • de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. (karger.com)
  • Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. (lu.se)
  • Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • In the present study, the case of a patient diagnosed with diffuse large B‑cell lymphoma, who received chemotherapy and autologous hematopoietic stem cell transplantation is presented. (spandidos-publications.com)
  • In the present study, the case of a patient with diffuse large B-cell lymphoma evolving from grade 3a follicular lymphoma, who maintained a complete response for 4-years, and then presented with severe isolated thrombocytopenia, is reported. (spandidos-publications.com)
  • The patient had been diagnosed 5 years prior to this presentation with diffuse large B-cell lymphoma evolving from grade 3a follicular lymphoma. (spandidos-publications.com)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30-40% of non-Hodgkin's lymphoma. (deepdyve.com)
  • Lymphoma is a type of blood cancer that develops when an error in the production of lymphocytes, a type of white blood cell found in the lymph nodes, results in abnormal cells that become cancerous. (lymphoma.ca)
  • Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. (clinicaltrialsregister.eu)
  • Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system. (ca.gov)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Most recently, data for the efficacy of the JCAR17 platform for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in the United States, were presented by Dr. Jeremy Abramson and his colleagues at the 2017 International Conference on Malignant Lymphoma. (medpagetoday.com)
  • Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions and possibly cure patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with poor prognosis and no standard therapeutic options. (medpagetoday.com)
  • Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Hodgkin lymphoma results from the clonal transformation of cells of B-cell origin, giving rise to pathognomic binucleated Reed-Sternberg cells. (msdmanuals.com)
  • After completion of the Run In, an aggressive lymphoma and an indolent lymphoma Dose Expansion cohort may open. (who.int)
  • Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
  • Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
Marrow transplantation7
Allogeneic5
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
Refractory9
  • The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. (elsevierpure.com)
  • Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. (elsevierpure.com)
  • Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. (elsevierpure.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • Research Objective We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment Impact Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production. (ca.gov)
  • Our preliminary experience with CARTs has been primarily against a variety of relapsed, refractory B-cell malignancies including ALL, CLL, and NHL. (medpagetoday.com)
  • Remarkably, this high degree of response was preserved in high-risk patients, including those who were refractory to chemotherapy after transplantation, or had double/triple hit lymphomas. (medpagetoday.com)
  • We are finding that CD-19 directed CARTs for relapsed/refractory DLBCL can induce remarkably durable remissions and cures in patients who previously had limited treatment options after being chemotherapy refractory, with an associated low chance of achieving remission and poor prognosis. (medpagetoday.com)
Multiple myeloma10
  • Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. (blogspot.com)
  • Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Multiple myeloma (MM) is a malignant plasma cell disorder with debilitating symptoms related to anemia, immunosuppression, bone destruction, and renal failure. (haematologica.org)
  • Multiple myeloma (MM), a clonal expansion of plasma cells, is characterised by monoclonal protein production, end-organ damage and marked clinical and genetic heterogeneity. (touchoncology.com)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • The study of 668 patients with newly-diagnosed multiple myeloma compared treatment with two courses of Celgene's Alkeran (melphalan) to the combination of Alkeran and Celgene's Thalomid brand of thalidomide alongside autologous stem cell transplantation. (pharmatimes.com)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
Rituximab2
  • In this analysis, BEXXAR was shown to have a favorable cost-effectiveness profile compared to alternative treatments, including chemotherapy, ZEVALIN (Ibritumomab Tiuxetan), and maintenance Rituximab. (salesandmarketingnetwork.com)
  • BEXXAR is currently being evaluated in a Phase III Southwest Oncology Group study evaluating CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine (Oncovin), and prednisone) chemotherapy in combination with Rituximab versus CHOP in combination with BEXXAR in patients with newly-diagnosed follicular NHL. (salesandmarketingnetwork.com)
Retrospective analysis1
Therapies10
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Despite best current therapies, patients with recurrent MB experience have an alarmingly high mortality rate and often have limited therapeutic options beyond inadequate chemotherapy or experimental clinical trials. (biomedcentral.com)
  • Although applying multi-modal therapies (radiation, chemotherapy, and surgery) has increased 5-year survival amongst standard-risk MB patients, overall survival (OS) rates seem to have plateaued. (biomedcentral.com)
  • Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). (ca.gov)
  • Background Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. (haematologica.org)
  • While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
  • CAR T-cell therapies are limited by the potential to cause life-threatening toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). (ajmc.com)
  • 14-17 Front-line treatment of MM can result in high response rates, 18-21 although all patients eventually relapse and more effective therapies are needed. (touchoncology.com)
BEAM1
  • After completion of the sequence, the patient will usually undergo pre-transplant conditioning chemotherapy regimen (such as BEAM) and then will get autologous stem cell transplantation as the final consolidation. (wikipedia.org)
Bone marrow5
  • Viral infection can lead to fatal complications in patients with weakened immune systems resulting from chemotherapy, bone marrow or cord blood transplant, and other forms of inherited or acquired disorders. (ca.gov)
  • Angiocrine is developing a cell therapy aimed to improve the availability and engraftment of blood stem cell transplants for cancer patients who have had their cancerous bone marrow removed by chemotherapy. (ca.gov)
  • Adult stem cells were firstly isolated from bone marrow in mice (Spangrude, Heimfeld, and Weissman, 1988) and later in humans. (bmrat.org)
  • Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
  • The prevalence production, lytic lesions and increased of leptomeningeal infiltration in breast can- plasma cells in the bone marrow [ 1 ]. (who.int)
Transplant6
Immunotherapy4
Progenitor1
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
Therapy25
  • The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. (elsevierpure.com)
  • New therapeutic concepts in anti-tumor therapy aim to modulate the patient's immune system to increase its aggressiveness or targeted effects toward tumor cells. (frontiersin.org)
  • Besides surgery, radiotherapy and chemotherapy, immune activation by direct application of cytokines, antibodies or adoptive cell therapy are promising approaches. (frontiersin.org)
  • A main challenge of NK cell therapy is that it requires a high amount of functional NK cells. (frontiersin.org)
  • In a proof of concept in vivo study, we also observed a therapeutic effect of adoptively transferred IL-15 expanded and IL-21 boosted NK cells in combination with image guided high precision radiation therapy using a luciferase-transduced RMS xenograft model. (frontiersin.org)
  • Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. (thieme-connect.de)
  • Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on positron-emission tomography (PET) scanning throughout the various regimens. (medscape.com)
  • Regimens that combine chemotherapy and radiation therapy (RT) have replaced RT alone for treatment of early-stage, favorable disease. (medscape.com)
  • Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
  • Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. (deepdyve.com)
  • The overall survival of patients older than 65 years, who did not receive a high-dose therapy, did not improve. (uni-wuerzburg.de)
  • The high-dose therapy with autologous stem cell retransfusion seems to be the most important factor to improve the overall survival of patients. (uni-wuerzburg.de)
  • Chimeric antigen receptor T cells (CARTs) are a novel cell-based therapy designed to direct host-derived T-cells against cancer cells through tumor-specific surface receptors. (medpagetoday.com)
  • 1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). (who.int)
  • Bridging therapy: For participants who are at high risk to experience disease progression during the manufacture of JNJ-90009530 drug product and before lymphodepletion, a bridging therapy is allowed at the investigator's discretion and Sponsor's approval. (who.int)
  • The process for administering CAR T-cell therapy is complex, with multiple steps including CAR T-cell manufacturing, lymphodepleting chemotherapy, cellular therapy infusion, and management of short-term and long-term toxicities. (ajmc.com)
  • Pharmacists are intricately involved in the process of providing CAR T-cell therapy both at the organizational level of budgeting and coordinating therapy and in direct patient care roles providing counseling and support for adverse effect management. (ajmc.com)
  • Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
  • Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
  • 1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
  • In addition, challenges related to manufacturing a patient-specific product, need for inpatient administration in a tertiary care setting, high costs and inadequate reimbursement have limited access to CAR T-cell therapy. (ajmc.com)
  • 2,3 Cellular therapy centers, manufacturers, payers, and policy makers will need to work together to address barriers to care as new CAR T-cell products with improved efficacy and tolerability are approved for use in more diverse malignancies. (ajmc.com)
  • For a long time, stem cells have been utilized to renew the immune system for radiation or chemo- therapy treated patients. (bmrat.org)
Combined chemotherapy and radiation2
  • The Nigro protocol, by the way, consists of combined chemotherapy and radiation and is still the standard of care for anal cancer. (sciencebasedmedicine.org)
  • Clinical scientists continue to observe superior survival of patients treated with combined chemotherapy and radiation approaches, yet the mechanisms behind this synergistic therapeutic approach are not fully understood. (mdanderson.org)
Lymphomas3
  • T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas. (cun.es)
  • The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
  • REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
Survival5
  • The mutation causes the cells to produce a distorted protein, which switches on the IRAK complex pathway, leading to activation of NF-kB, a protein that is essential for the growth and survival of Waldenström's tumor cells," Treon comments. (sciencedaily.com)
  • In vivo development and survival of NK cells require cytokines ( 6 - 8 ). (frontiersin.org)
  • published a randomized prospective trial that showed a median survival of more than 3 years in patients who went through a high-dosed chemotherapy and autologous stem cell transplantation. (uni-wuerzburg.de)
  • Thalomid was also associated with higher event-free survival at five years (56% versus 43%), but the overall survival rate was no different at 65% a piece. (pharmatimes.com)
  • If complications and intracranial plasmacyto- survival were prolonged, the prevalence of mas with no further discussion of the other leptomeningeal MM might be higher. (who.int)
Tumors6
  • MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group study 26951. (thieme-connect.de)
  • The cancer cells use that protein to evade the component of our immune system that routinely destroys tumors. (ca.gov)
  • Research Objective LGR5-antibody drug conjugate to target LIC in B cell tumors that undergo self-renewal Impact LIC were only defined in myeloid leukemia, while LIC populations in B cell tumors remain elusive. (ca.gov)
  • LICs give rise to drug-resistance and relapse and remain unsolved clinical problems in B cell tumors. (ca.gov)
  • Design and Methods OPM2 and high-risk primary myeloma tumors were grown in human fetal bone implanted into non-obese diabetic severe combined immunodeficiency mice with a deficient interleukin-2 receptor gamma chain. (haematologica.org)
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
HSCT2
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
Tumor cells10
  • The discovery was made by sequencing the genome of tumor cells in Waldenström's patients, reading the cells' DNA letter by letter, and seeing where it differed from that of the patients' normal cells. (sciencedaily.com)
  • We found that tumor cells in 90 percent of the patients we tested contained a single point mutation, an error in one of the bases that make up the 'rungs' of the DNA helix," says Steven Treon, MD, PhD, who led the research with his Dana-Farber colleague Zachary Hunter. (sciencedaily.com)
  • In subsequent experiments, when we treated the tumor cells with drugs that target the pathway activated by the mutated gene, the cells underwent apoptosis, or programmed cell death. (sciencedaily.com)
  • These results suggest that new, effective treatments that target the tumor cells directly are now possible for people with the disease. (sciencedaily.com)
  • For the current research, Treon and his colleagues conducted whole genome sequencing of tumor cells and normal cells from 30 patients with Waldenström's. (sciencedaily.com)
  • In collaboration with Complete Genomics of Mountain View, Calif., researchers "lined up" the sequences of the tumor and non-tumor cells to identify differences. (sciencedaily.com)
  • Ninety percent of the tumor cells had a point mutation in the gene MYD88. (sciencedaily.com)
  • When we shut down the pathway by blocking the abnormal protein with drug molecules, the tumor cells entered apoptosis. (sciencedaily.com)
  • This specific construct consists of equal quantities of CD4+/CD8+ CARTs which are transduced separately after apheresis and directed against CD-19 on tumor cells subsequently in a 1:1 infusion. (medpagetoday.com)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
Post-transplantation1
  • Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. (karger.com)
Irradiation1
  • Treatment involves maximal safe tumor resection, craniospinal irradiation, and high-dose chemotherapy. (biomedcentral.com)
Clinical3
  • Many culturing strategies are based on the addition of feeder or accessory cells, which need to be removed prior to the clinical application of the final NK cell product. (frontiersin.org)
  • Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. (deepdyve.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
Myeloma4
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • The transferred, expanded natural killer cells proliferated in vivo in an interleukin-2 dose-dependent fashion, persisted up to 4 weeks, were readily detectable in the human bone, inhibited myeloma growth and protected bone from myeloma-induced osteolysis. (haematologica.org)
Hematopoietic stem4
  • Effects of oxygen metabolites/chemokines on hematopoietic stem cell expansion and preservation. (rochester.edu)
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
  • He was treated with chemotherapy (8 R-CHOP protocols) with partial response, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation, with a complete response, and was stable for the previous 4 years. (spandidos-publications.com)
  • and hematopoietic stem cell safety. (cdc.gov)
Patient6
  • The idea behind this approach is that when using single-agent chemotherapy, the doctor can easily escalate the dose of the drug to the maximum tolerable dose by the patient, avoiding additive hematological toxicity from chemotherapeutic combinations, and thus improving efficacy. (wikipedia.org)
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment. (karger.com)
  • While the doctor-patient relationship is one of potential intensity and privacy, the best patient care comes from teamwork, which values all who contribute to achieving high-quality care with compassion. (rochester.edu)
  • There is not a single cancer patient that has ever been cured by chemotherapy. (sciencebasedmedicine.org)
  • From a cancer patient population and public health perspective, cancer chemotherapy (chemo) has been a major medical advance . (sciencebasedmedicine.org)
  • BEXXAR, which is given in four visits over one to two weeks, is specifically dosed based on an individual's drug clearance rate, allowing the delivery of a predetermined amount of radiation to each patient. (salesandmarketingnetwork.com)
Malignancies2
  • Most of these malignancies are of B-cell origin. (oncolink.org)
  • Nevertheless, as the CART repertoire expands to other B-cell malignancies and solid cancers, we can expect to see further studies investigating potential variables regarding their function in various settings. (medpagetoday.com)
Malignant cells4
  • In the last years, adoptive transfer of natural killer (NK) cells came into the focus of translational medicine, because of their high cytotoxic potential against transformed malignant cells. (frontiersin.org)
  • With their ability to detect and directly destroy virally infected or malignant cells, natural killer (NK) cells form an important part of the first line defense of the immune system. (frontiersin.org)
  • The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
  • The five-year study revealed that the complete response rate among the Thalomid group, defined as the disappearance of malignant cells in the blood, was 62%, significantly higher than the 43% seen in the control group. (pharmatimes.com)
Infusion2
  • Although arterial infusion chemotherapy (pirarubicin hydrochloride and carboplatin) was given, no tumor shrinkage was observed, and surgery was therefore performed to remove the tumor. (karger.com)
  • Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. (druglib.com)
Antigen2
  • SummaryChimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. (deepdyve.com)
  • Combined, these agents form a radiolabeled monoclonal antibody regimen that is able to bind to the target antigen CD20 found on B cells, including normal B-cells and those that become cancerous in NHL, thereby delivering the dose of radiation. (salesandmarketingnetwork.com)
METHODS1
  • In this study, we addressed feeder cell-free expansion methods using common γ-chain cytokines, especially IL-15 and IL-21. (frontiersin.org)
Treatment8
  • In summary, this two-phased feeder cell-free ex vivo culturing protocol combined efficient expansion and high cytolytic functionality of NK cells for treatment of radiation-resistant RMS. (frontiersin.org)
  • Meanwhile, the real quackery is found in the pushing of toxic chemotherapy chemicals that are injected into the bodies of patients and called "treatment" when they should really be called "torture. (sciencebasedmedicine.org)
  • Impact Treatment of the cancer stem cell driven disease Acute Myelogenous Leukemia (AML) will be impacted. (ca.gov)
  • Stem cells are not only widely used for regenerative medicine, but are also considered as a useful tool for cancer treatment. (bmrat.org)
  • Cancer vaccines based on the knowledge of cancer stem cells have been studied and applied for cancer treatment. (bmrat.org)
  • This re- view discusses stem cell applications in transplantation, stem cell-based carriers, induced-pluripotent stem cells, can- cer stem cells, and potential of stem cells engineering to revolutionize cancer treatment. (bmrat.org)
  • The combination treatment was also associated with higher rates of blood clots and damage to the nerves. (pharmatimes.com)
  • Thalidomide, originally used as a treatment for morning sickness, was taken off the market in the 1960s because women who took it during pregnancy had a much higher rate of severe birth defects. (pharmatimes.com)
Acute Myelogen1
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
Sequential1
  • Sequential high-dose chemotherapy is a chemotherapy regimen consisting of several (2 to 4) sequential monochemotherapies with only one chemotherapeutic agent per course. (wikipedia.org)
Phase1
  • Hence, we established a two-phase expansion protocol with IL-15 to induce an early NK cell expansion, followed by short exposure to IL-21 that boosted the cytotoxic activity of NK cells against RMS cells. (frontiersin.org)
Pediatric1
  • T cell PTLD is rare, particularly in pediatric patients. (karger.com)